Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
J Pediatr Gastroenterol Nutr ; 32(3): 278-86, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11345176

ABSTRACT

BACKGROUND: The purpose of this study was to evaluate retrospectively the value of leukocyte-labeled scintigraphy, ultrasonography, and contrast radiography compared with endoscopy in children suspected of having inflammatory bowel disease (IBD). METHODS: Twenty-eight children (17 boys; mean age, 10.2 years) with IBD based on standard colonoscopic, histologic, and radiologic criteria (16 with Crohn's disease, 5 with ulcerative colitis, 5 with nonspecific colitis, I with granulomatous disease, and I with Beh,cet's disease) were included. Endoscopic, ultrasonographic, and contrast radiologic examinations were realized for 28, 23, and 19 children respectively. RESULTS: Sensitivity and specificity were 75% and 92% for leukocyte-labeled scintigraphy, 39% and 90% for ultrasonography, and 58% and 83% for contrast radiography. The authors noted discontinuous uptake for 14 of 15 true-positive results for patients with Crohn's disease and continuous uptake for 4 of 4 true-positive results for patients with ulcerative colitis. A negative correlation between scan activity index and Lloyd-Still clinical score was found for 11 patients with Crohn's disease (r = -0.77). CONCLUSIONS: Leukocyte-labeled scintigraphy, a noninvasive and reproducible technique, is a useful tool in the diagnosis and therapeutic strategy of IBD, and provides information on the presence, the intensity, and the extent of the disease, particularly in the terminal ileum. Leukocyte-labeled scintigraphy may not replace colonoscopy with biopsies for diagnosis confirmation. Its reliability seems higher than that of ultrasonography.


Subject(s)
Inflammatory Bowel Diseases/diagnosis , Radiopharmaceuticals , Technetium Tc 99m Exametazime , Adolescent , Barium Compounds , Child , Child, Preschool , Colitis, Ulcerative/diagnostic imaging , Colonoscopy , Crohn Disease/diagnostic imaging , Diagnosis, Differential , Female , Humans , Inflammatory Bowel Diseases/diagnostic imaging , Leukocytes , Male , Radiography , Radionuclide Imaging , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Ultrasonography
2.
Rheumatology (Oxford) ; 38(6): 543-6, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10402075

ABSTRACT

OBJECTIVE: To study the concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO)-labelled leucocytes (ASTLL) and ileocolonoscopy in patients with spondyloarthropathies (SpA) and without clinical evidence of inflammatory bowel disease (IBD). PATIENTS AND METHODS: Fifteen patients with SpA (European Spondylarthropathy Study Group 1991 criteria) without clinical evidence of IBD were studied prospectively with ASTLL and ileocolonoscopy. RESULTS: This cohort consisted of seven men and eight women aged 31.8+/-10.5 yr (18-47) [mean age +/- S.D. (range)] and with a disease duration of 6.0+/-4.4 yr (0.4-15). ASTLL showed abnormal uptake in four patients. Ileocolonoscopy was abnormal in five patients, showing acute inflammatory lesions in one patient with reactive arthritis, undifferentiated chronic inflammatory lesions in two cases, and features indistinguishable from those of Crohn's disease in two cases. ASTLL was negative in two cases in which ileocolonoscopy showed inflammatory lesions and was positive (terminal ileum) in one case with normal ileocolonoscopy. The concordance between the two examinations was statistically significant (kappa = 0.53; P = 0.008). CONCLUSION: ASTLL may be an interesting tool to detect subclinical gut inflammation in patients with SpA.


Subject(s)
Abdomen/diagnostic imaging , Colonoscopy/standards , Inflammatory Bowel Diseases/diagnosis , Radionuclide Imaging/standards , Spondylitis, Ankylosing/complications , Adolescent , Adult , Female , Humans , Inflammatory Bowel Diseases/pathology , Leukocytes , Male , Middle Aged , Prospective Studies , Reproducibility of Results , Spondylitis, Ankylosing/pathology , Technetium Tc 99m Exametazime
3.
J Hepatol ; 20(3): 336-42, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8014443

ABSTRACT

Possible associations between particular human leucocyte antigen molecules and immunoallergic hepatitis have been suggested previously (HLA-A11 in halothane hepatitis, HLA-DR6 and DR2 in nitrofurantoin hepatitis, HLA-B8 in clometacin hepatitis). In this study the HLA haplotype was determined in 71 patients with idiosyncratic hepatitis due to different drugs. The prevalence of HLA-A11 was twice as high in the 71 patients in the study (23%) as in controls (12%), but p-values were not significant when corrections were made for the large number of comparisons (n = 39). The prevalences of HLA-DR2, DR6, and B8 were similar in the 71 patients and in controls. When hepatitis due to particular drugs was considered, HLA-A11 was found to be present in six of 12 patients (50%) with hepatitis caused by tricyclic antidepressants, and three of four patients (75%) with diclofenac hepatitis, compared to 12% in controls. HLA-DR6 was present in four of five patients (80%) with chlorpromazine hepatitis, compared to 22% in controls. In conclusion, the HLA phenotype does not contribute significantly to idiosyncratic drug-induced hepatitis considered collectively. Possible associations between some HLA molecules and the hepatotoxicity of certain drugs require further confirmation.


Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/immunology , Diclofenac/adverse effects , HLA Antigens/physiology , Halothane/adverse effects , Nitrofurantoin/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Chlorpromazine/adverse effects , Female , HLA Antigens/genetics , HLA-A Antigens/chemistry , HLA-A Antigens/genetics , HLA-A11 Antigen , HLA-B8 Antigen/genetics , HLA-B8 Antigen/physiology , HLA-DR2 Antigen/genetics , HLA-DR2 Antigen/physiology , HLA-DR6 Antigen/genetics , HLA-DR6 Antigen/physiology , Haplotypes , Humans , Male , Middle Aged , Phenotype
5.
J Clin Invest ; 90(5): 1679-86, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1430199

ABSTRACT

We studied metabolic, polypeptide and genetic variation in eight glutaric acidemia type II (GA II) patients with electron transfer flavoprotein (ETF) deficiency. As measured by 3H-fatty acid oxidations in fibroblasts, beta-oxidation pathway flux correlated well with clinical phenotypes. In six patients with severe neonatal onset GA II, oxidation of [9,10(n)-3H]-palmitate ranged from 2% to 22% of control and of [9,10(n)-3H]myristate, from 2% to 26% of control. Of two patients with late onset GA II, one had intermediate residual activities with these substrates and the other normal activities. Radiolabeling and immunoprecipitation studies revealed that three of the six neonatal onset GA II patients had greatly diminished or absent alpha- and beta-ETF subunits, consistent with a failure to assemble a stable heterodimer. Another neonatal onset patient showed normal synthesis of beta-ETF but decreased synthesis of alpha-ETF. Two neonatal onset and two late onset GA II patients showed normal synthesis of both subunits. Analysis of the pre-alpha-ETF coding sequence revealed seven different mutations in the six patients with neonatal onset GA II. The most common mutation was a methionine for threonine substitution at codon 266 found in four unrelated patients, while all the other mutations were seen in single patients. No mutations were detected in the two patients with late onset GA II.


Subject(s)
Amino Acid Metabolism, Inborn Errors/metabolism , DNA/genetics , Fatty Acids/metabolism , Flavoproteins/genetics , Glutarates/blood , Lipid Metabolism, Inborn Errors/metabolism , Peptide Biosynthesis , Amino Acid Metabolism, Inborn Errors/genetics , Base Sequence , Cells, Cultured , Electron-Transferring Flavoproteins , Humans , Lipid Metabolism, Inborn Errors/genetics , Molecular Sequence Data , Mutation , Oxidation-Reduction , Polymerase Chain Reaction
6.
Pediatr Res ; 31(6): 552-6, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1635815

ABSTRACT

BALB/cByJ (J) mice have short-chain acyl-CoA dehydrogenase (SCAD) deficiency and an organic aciduria similar to that of human SCAD deficiency. [9,10(n)-3H]- and [15,16(n)-3H]palmitate oxidations in J mouse fibroblasts were 96 and 35% of control, respectively, consistent with an isolated SCAD defect. Acyl-CoA dehydrogenase activities were assayed in muscle and fibroblast mitochondria from BALB/cBy controls (Y) and SCAD-deficient J mice. Medium-chain acyl-CoA dehydrogenase (MCAD) activities were comparable in both J and Y mice from all tissues. In the presence of MCAD antiserum, SCAD activities in J mice were undetectable in both tissues. Apparent Km and Vmax values in liver mitochondria suggested a somewhat increased affinity of MCAD for butyryl-CoA in J mice, as compared with MCAD from other species. Immunoblot studies using mitochondria revealed identical apparent SCAD molecular weight in liver, muscle, and fibroblasts from Y mice and no detectable SCAD antigen in J mice; MCAD antigen was detected in comparable amounts from both Y and J mice. Radiolabeling and immunoprecipitation studies in J mouse fibroblasts revealed no SCAD synthesis, but normal MCAD synthesis. These data argue against the existence of tissue-specific SCAD isoforms in the mouse and confirm that this mouse strain is a model for the human organic aciduria resulting from this beta-oxidation defect.


Subject(s)
Acyl-CoA Dehydrogenases/deficiency , Acyl-CoA Dehydrogenase , Acyl-CoA Dehydrogenases/genetics , Acyl-CoA Dehydrogenases/immunology , Acyl-CoA Dehydrogenases/metabolism , Animals , Antigens/analysis , Fibroblasts/enzymology , Immunochemistry , Kinetics , Liver/enzymology , Mice , Mice, Inbred BALB C , Mice, Mutant Strains , Muscles/enzymology , Tissue Distribution
7.
Neurology ; 41(12): 1957-60, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1660571

ABSTRACT

A patient presenting in the first year of life with feeding difficulties and failure to grow had variable but persistent lactic acidemia noted at age 20 months. Nonspecific nutritional and biochemical therapy was accompanied by improvement in general clinical status, growth, gait, and development. However, she died in a catastrophic illness at the end of the third year of life. Studies in intact fibroblast mitochondria were consistent with an isolated but partial defect in cytochrome c oxidase. On direct assay of this enzyme complex in fibroblast homogenates and mitochondria, activity was much more severely depressed (less than or equal to 8% of control). Her fibroblasts normally synthesized the three cytochrome c oxidase subunits encoded on the mitochondrial genome. These data confirm that this patient had cytochrome c oxidase deficiency and demonstrate significant biochemical heterogeneity, since the results of the intact mitochondrial studies correlate better with her clinical course than do those of the direct enzymatic assays.


Subject(s)
Cytochrome-c Oxidase Deficiency , Fibroblasts/metabolism , Cells, Cultured , Child, Preschool , Electrophoresis, Polyacrylamide Gel , Failure to Thrive/metabolism , Female , Humans , Lactates/blood , Lactic Acid , Mitochondria/metabolism
9.
J Pharmacol Exp Ther ; 255(2): 529-35, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2123005

ABSTRACT

The effects of the R-(-) and S-(+)ibuprofen enantiomers were first studied in vitro with mouse liver mitochondria incubated in the presence of various concentrations of exogenous coenzyme A. In the presence of a low concentration of coenzyme A (2.5 microM), the R-(-)enantiomer (which forms an acylcoenzyme A) inhibited stereoselectively the beta oxidation of [1-14C]palmitic acid but not that of [1-14C]palmitoyl-L-carnitine (which can directly enter the mitochondria). In the presence, however, of a concentration of coenzyme A (50 microM) reproducing that present in liver cell cytosol, both enantiomers (2 mM) slightly inhibited the beta oxidation of [1-14C]palmitic acid and markedly inhibited the beta oxidation of [1-14C]octanoic acid and [1-14C]butyric acid. In vivo, both enantiomers (1 mmol.kg-1) similarly inhibited the formation of [14C]CO2 from [1-14C]fatty acids. Both enantiomers similarly decreased plasma ketone bodies. Both similarly increased hepatic triglycerides, and both produced mild microvesicular steatosis of the liver. We conclude that both ibuprofen enantiomers inhibit beta oxidation of fatty acids in vitro and in vivo. In addition, the R-(-)enantiomer may stereoselectively sequester coenzyme A; at low concentrations of coenzyme A in vitro, this may stereoselectively inhibit the mitochondrial uptake and beta oxidation of long chain fatty acids.


Subject(s)
Fatty Acids/metabolism , Ibuprofen/pharmacology , Mitochondria, Liver/drug effects , Animals , Carbon Dioxide/metabolism , Carbon Radioisotopes , In Vitro Techniques , Ketone Bodies/blood , Lipid Metabolism , Male , Mice , Mice, Inbred ICR , Mitochondria, Liver/metabolism , Oxidation-Reduction , Rats , Rats, Inbred Strains , Stereoisomerism
10.
J Clin Gastroenterol ; 12(3): 329-31, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2362104

ABSTRACT

Tetrahydroaminoacridine administration has been proposed as a treatment for Alzheimer's disease. Although recent studies have shown that tetrahydroaminoacridine administration can be associated with mild or moderate liver dysfunction, to our knowledge, no case of symptomatic hepatitis with severe liver lesions has heretofore been reported. We describe a patient who developed jaundice after receiving tetrahydroaminoacridine for three weeks. Histologic examination showed extensive hepatocellular necrosis. Tetrahydroaminoacridine withdrawal was followed by the disappearance of jaundice within a few days and complete recovery within 5 weeks. This case shows that tetrahydroaminoacridine administration can induce marked liver cell necrosis resulting in symptomatic acute hepatitis.


Subject(s)
Alzheimer Disease/drug therapy , Aminoacridines/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Tacrine/adverse effects , Acute Disease , Aged , Chemical and Drug Induced Liver Injury/pathology , Female , Humans , Liver/pathology , Necrosis
11.
Biochem Pharmacol ; 38(21): 3743-51, 1989 Nov 01.
Article in English | MEDLINE | ID: mdl-2597170

ABSTRACT

Tianeptine is a new tricyclic antidepressant which is metabolized mainly by beta-oxidation of its heptanoic side chain. We determined the effects of tianeptine on the mitochondrial oxidation of natural fatty acids in mice. In vitro, tianeptine (0.5 mM) inhibited by only 32% the formation of beta-oxidation products from [1-14C]palmitic acid by hepatic mitochondria, but inhibited by 71% that from [1-14C]octanoic acid and by 51% that from [1-14C]butyric acid. The activity of the tricarboxylic acid cycle, assessed as the in vitro formation of [14C]CO2 from [1-14C]acetylcoenzyme A was decreased by 51% in the presence of tianeptine (0.5 mM). The inhibition of both beta-oxidation and the tricarboxylic acid cycle appeared reversible in mitochondria from mice exposed to tianeptine in vivo but incubated in vitro without tianeptine. In vivo, administration of tianeptine (0.0625 mmol/kg i.p.), decreased by 53 and 58%, respectively, the formation of [14C]CO2 from [1-14C]octanoic acid and [1-14C]butyric acid, but did not significantly decrease that from [1-14C]palmitic acid. After administration of high doses of tianeptine, however, formation of [14C]CO2 from [1-14C]palmitic acid became inhibited as well, transiently after 0.25 mmol/kg and durably (greater than 24 hr) after 0.75 mmol/kg i.p. Hepatic triglycerides were increased 24 hr after administration of 0.75 mmol/kg i.p. of tianeptine, but not after 0.25 mmol/kg i.p. Microvesicular steatosis of the liver was observed in some mice after 0.75 mmol/kg i.p., but not after 0.5 mmol/kg i.p. We conclude that tianeptine inhibits the oxidation of medium- and short-chain fatty acids in mice. Microvesicular steatosis, however, requires very large doses in mice (0.75 mmol/kg i.p., i.e. 600-times the oral dose in humans), and is therefore unlikely to occur in humans.


Subject(s)
Antidepressive Agents, Tricyclic/metabolism , Fatty Acids/metabolism , Heptanoic Acids/metabolism , Mitochondria, Liver/drug effects , Thiazepines/metabolism , Animals , Antidepressive Agents, Tricyclic/pharmacology , Blood Glucose/analysis , Fatty Acids/analysis , Fatty Liver/chemically induced , Fatty Liver/metabolism , Ketone Bodies/blood , Male , Mice , Mitochondria, Liver/analysis , Mitochondria, Liver/metabolism , Molecular Structure , Oxidation-Reduction/drug effects , Thiazepines/pharmacology , Time Factors , Triglycerides/analysis , Triglycerides/metabolism
12.
Biochem Pharmacol ; 38(19): 3241-6, 1989 Oct 01.
Article in English | MEDLINE | ID: mdl-2818623

ABSTRACT

Incubation under air of [14C]tianeptine (0.5 mM) with a NADPH-generating system and hamster, mouse or rat liver microsomes resulted in the in vitro covalent binding of [14C]tianeptine metabolites to microsomal proteins. Covalent binding to hamster liver microsomes required NADPH and oxygen; it was decreased in the presence of the cytochrome P-450 inhibitors, carbon monoxide, piperonyl butoxide (4 mM), and SKF 525-A (4 mM) or in the presence of the nucleophile, glutathione (1 or 4 mM). In vitro covalent binding to hamster liver microsomes was not decreased in the presence of quinidine (1 microM), and was similar with microsomes from either female Dark Agouti, or female Sprague-Dawley rats. In contrast, in vitro covalent binding to hamster liver microsomes was decreased in the presence of troleandomycin (0.25 mM), while covalent binding was increased with microsomes from either hamsters, mice or rats pretreated with dexamethasone. Preincubation with IgG antibodies directed against rabbit liver glucocorticoid-inducible cytochrome P-450 3c(P-450 IIIA4) decreased in vitro covalent binding by 53 and 89%, respectively, with microsomes from control hamsters and dexamethasone-pretreated hamsters, and by 60 and 81%, respectively, with microsomes from control and dexamethasone-pretreated rats. We conclude that tianeptine is activated by hamster, mouse and rat liver cytochrome P-450 into a reactive metabolite. Metabolic activation is mediated in part by glucocorticoid-inducible isoenzymes but not by the isoenzyme metabolizing debrisoquine. In vivo studies are reported in the accompanying paper.


Subject(s)
Antidepressive Agents, Tricyclic/metabolism , Cytochrome P-450 Enzyme System/physiology , Thiazepines/metabolism , Animals , Biotransformation , Cricetinae , Dexamethasone/pharmacology , In Vitro Techniques , Male , Mesocricetus , Mice , Microsomes, Liver/metabolism , Rats , Rats, Inbred Strains
13.
Br J Clin Pharmacol ; 28(3): 297-304, 1989 Sep.
Article in English | MEDLINE | ID: mdl-2789923

ABSTRACT

1. The O-demethylation of dextromethorphan to dextrorphan exhibits a genetically-controlled polymorphism, co-segregating with that of debrisoquine hydroxylation. Dextromethorphan has been proposed as a test compound to assess drug oxidation polymorphism. 2. We studied the effects of liver disease of varying severity on dextromethorphan oxidation capacity. Phenotyping was performed using the urinary dextromethorphan/dextrorphan metabolic ratio after oral administration of 40 mg dextromethorphan hydrobromide in 56 patients with cirrhosis and in 51 patients with moderately severe liver disease. 3. Dextromethorphan oxidation capacity was impaired in cirrhotic patients and, to lesser extent, in non cirrhotic patients, as compared with 103 control subjects. 4. The impairment in dextromethorphan oxidation induced by liver disease, was however, much less than that caused by the genetic deficiency. As a result, the prevalence of the poor metabolizer phenotype remained in the same range in patients with cirrhosis (1.8%) and with moderately severe disease (2.0%) as in controls (3.9%). 5. This observation shows that, although liver disease causes some impairment of dextromethorphan O-demethylation, this impairment is not sufficient to modify the assignment of phenotypes.


Subject(s)
Dextromethorphan/metabolism , Levorphanol/analogs & derivatives , Liver Diseases/metabolism , Adult , Aged , Aged, 80 and over , Creatinine/blood , Dextrorphan/urine , Female , Humans , Liver Cirrhosis, Alcoholic/metabolism , Liver Function Tests , Male , Middle Aged , Oxidation-Reduction , Phenotype
14.
Hepatology ; 10(2): 168-73, 1989 Aug.
Article in English | MEDLINE | ID: mdl-2744728

ABSTRACT

Amineptine-induced immunoallergic hepatitis is unpredictable. It may be related to its oxidation into a reactive metabolite acting as hapten. We have looked for a possible genetic predisposition involving drug oxidation capacity and/or cell defense mechanisms in nine patients with previous amineptine hepatitis. Drug oxidation capacity was assessed using dextromethorphan, a test compound recently proposed as a substitute for debrisoquine. The eight patients tested had the extensive metabolizer phenotype. The susceptibility to amineptine metabolites was studied by an in vitro test assessing the destruction of the patients' lymphocytes by reactive metabolites generated from amineptine by a standardized oxidation microsomal system. Lymphocyte death increased with the dose of amineptine (1 to 2.5 mM); it was increased by preincubation with trichloropropene oxide, but was absent when amineptine was omitted or when the oxidation system was not operating. Mean lymphocyte death was twice higher in the nine patients with amineptine hepatitis than in 17 healthy controls. In contrast, when the test was performed with acetaminophen (3 to 10 mM), lymphocyte death was similar in controls and in patients. Basal epoxide hydrolase activity toward benzo[a]pyrene-4,5-oxide and glutathione concentration was similar in lymphocytes from controls and patients. Family studies showed an increased susceptibility to amineptine metabolites in lymphocytes from several first-degree relatives of two patients. These results show that amineptine hepatitis occurs in patients with extensive dextromethorphan oxidation capacity but with an increased susceptibility to amineptine reactive metabolites, probably related to a genetic deficiency in a cell defense mechanism.


Subject(s)
Antidepressive Agents, Tricyclic/adverse effects , Chemical and Drug Induced Liver Injury/genetics , Dibenzocycloheptenes/adverse effects , Adolescent , Adult , Antidepressive Agents, Tricyclic/toxicity , Cell Survival , Dextromethorphan/urine , Dextrorphan/urine , Dibenzocycloheptenes/toxicity , Family Health , Female , Humans , Lymphocytes/drug effects , Male , Middle Aged , Oxidation-Reduction , Phenotype
16.
J Hepatol ; 8(2): 158-64, 1989 Mar.
Article in English | MEDLINE | ID: mdl-2715619

ABSTRACT

The influence of genetically determined oxidation polymorphism on drug hepatotoxicity has been poorly investigated and results are controversial. We studied drug oxidation capacity in 51 patients with hepatitis caused mainly by drugs undergoing oxidative metabolism, using dextromethorphan, a test compound recently proposed as a substitute for debrisoquine. Phenotyping was performed using the metabolic ratio (MR) calculated as MR = 0-10 h urinary output of dextromethorphan/0-10 h urinary output of dextrorphan (the main oxidative metabolite), after oral administration of 40 mg dextromethorphan hydrobromide. Dextromethorphan oxidation capacity was similar in patients and in 103 control subjects as judged by: (a) the prevalence of each phenotype (5.9% versus 3.9% for the poor metabolizer phenotype and 94.1% versus 96.1% for the extensive metabolizer phenotype; (b) the frequency distribution histograms of log metabolic ratio; (c) the mean values of dextromethorphan and dextrorphan urinary outputs and of log metabolic ratio for each phenotype. These results show that hepatotoxicity of several drugs, including amineptine, amodiaquine and Plethoryl, is related neither to an impairment in dextromethorphan oxidation capacity nor to an unusually high capacity to oxidize this drug.


Subject(s)
Chemical and Drug Induced Liver Injury/genetics , Dextromethorphan/metabolism , Levorphanol/analogs & derivatives , Polymorphism, Genetic , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Dextrorphan/urine , Female , Humans , Male , Middle Aged , Oxidation-Reduction , Phenotype
17.
Biochem Pharmacol ; 38(6): 941-7, 1989 Mar 15.
Article in English | MEDLINE | ID: mdl-2930595

ABSTRACT

The effects of nilutamide were studied first with human liver microsomes. At concentrations expected in the human liver (110 microM), nilutamide inhibited hexobarbital hydroxylase, benzphetamine N-demethylase, benzo(a)pyrene hydroxylase and 7-ethoxycoumarin O-deethylase activities by 85, 40, 35 and 25%, respectively. There was no in vitro inhibition of NADPH-cytochrome c reductase activity, no in vitro loss of CO-binding cytochrome P-450, and no spectral evidence for the in vitro formation of a possible cytochrome P-450Fe(II)-nitroso metabolite complex. Other studies were performed with mouse liver microsomes. Nilutamide (550 microM) did not significantly increase the consumption of NADPH by aerobic microsomes, and did not modify the kinetics for the reduction of cytochrome P-450 by NADPH-cytochrome P-450 reductase in an anaerobic system. Nilutamide (22 microM) produced either a type I or a type II binding spectrum. Kinetics for the inhibition of hexobarbital hydroxylase were consistent with competitive inhibition. A last series of experiments was performed after administration of nilutamide in mice. Thirty minutes after administration of doses (15 or 30 mumol.kg-1 i.p.) similar to those used in humans, the hexobarbital sleeping time was increased by 40 and 60%, respectively. There was no evidence, however, for the irreversible inactivation of microsomal enzymes since CO-binding cytochrome P-450 and monooxygenase activities remained unchanged in liver microsomes from mice killed 1 or 6 hr after administration of nilutamide (30 mumol.kg-1 i.p.). These results show that nilutamide inhibits hepatic cytochrome P-450 activity, and suggest that inhibition may actually occur after therapeutic doses of nilutamide in humans.


Subject(s)
Androgen Receptor Antagonists , Cytochrome P-450 Enzyme Inhibitors , Imidazoles/pharmacology , Imidazolidines , Microsomes, Liver/enzymology , Animals , Binding, Competitive , Cytochrome P-450 Enzyme System , Dose-Response Relationship, Drug , Humans , Kinetics , Male , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Mixed Function Oxygenases/antagonists & inhibitors , NADP/metabolism , Oxidation-Reduction/drug effects , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Spectrophotometry
18.
J Pharmacol Exp Ther ; 247(2): 745-50, 1988 Nov.
Article in English | MEDLINE | ID: mdl-3183967

ABSTRACT

Microvesicular steatosis of the liver has been reported in two subjects receiving amineptine (a tricyclic antidepressant metabolized by beta-oxidation of its acyl chain). A similar disease is observed after ingestion of drugs which inhibit hepatic mitochondrial fatty acid beta-oxidation, or in subjects with various inborn defects in this metabolic pathway. We therefore determined the effects of amineptine on the mitochondrial oxidation of fatty acids in mice. In vitro, the formation of beta-oxidation products during incubation of palmitic acid with mouse liver mitochondria and the various cofactors necessary for beta-oxidation was inhibited by 27, 33, 46 and 57% respectively, in the presence of 0.25, 0.5, 1 and 2 mM of amineptine. Inhibition was reversible. Tricarboxylic acid cycle activity, assessed by the in vitro formation of [14C]CO2 from [1-14C]acetyl coenzyme A by mouse liver mitochondria, was inhibited by 22, 23, 47, 54, 60 and 62%, respectively, in the presence of 0.0625, 0.125, 0.25, 0.5, 1 and 2 mM of amineptine. In vivo, administration of amineptine, 0.5 and 0.75 mmol.kg-1, inhibited by 70 and 84%, respectively, the exhalation of [14C] CO2 during the first 3 hr after the administration of a tracer dose of [U-14C]palmitic acid. Administration of amineptine, 0.0625, 0.25, 0.5 or 1 mmol.kg-1, 6 hr before the measurement, increased hepatic triglycerides by 73, 139, 295 and 320%, respectively. After 1 mmol.kg-1, accumulation of hepatic triglycerides was maximum at 24 hr, reaching 5-fold the control value; liver histology at that time showed microvesicular steatosis.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antidepressive Agents, Tricyclic , Chemical and Drug Induced Liver Injury , Dibenzocycloheptenes , Fat Necrosis/chemically induced , Fatty Acids/metabolism , Mitochondria, Liver/metabolism , Necrosis/chemically induced , Acetyl Coenzyme A/metabolism , Animals , Breath Tests , Fat Necrosis/metabolism , Ketone Bodies/blood , Mice , Microcirculation , Oxidation-Reduction , Palmitic Acid , Palmitic Acids/metabolism
19.
Hepatology ; 8(5): 1056-62, 1988.
Article in English | MEDLINE | ID: mdl-3417225

ABSTRACT

Intravenous administration of high doses of tetracycline may produce severe microvesicular steatosis of the liver in man. A similar disease is observed after ingestion of drugs which inhibit hepatic mitochondrial fatty acid beta-oxidation and in subjects with various inborn defects in this metabolic pathway. We therefore determined the effects of tetracycline on the mitochondrial oxidation of fatty acids in mice and in man. In vitro, addition of tetracycline 0.25, 0.5, 1 or 2 mM inhibited by 15, 38, 56 and 65%, respectively, the formation of beta-oxidation products during incubation of palmitic acid with mouse liver mitochondria and the various cofactors necessary for beta-oxidation. Inhibition was reversible. Inhibition appeared even greater with human liver mitochondria. Tricarboxylic acid cycle activity, assessed by the in vitro formation of [14C]CO2 from [1-14C]acetylcoenzyme A by mouse liver mitochondria, was inhibited by 25, 32 and 43%, respectively, in the presence of 0.5, 1 or 2 mM of tetracycline. In vivo, administration of tetracycline, 0.25 or 1 mmole per kg, inhibited by 53 and 84%, respectively, the exhalation of [14C]CO2 during the first 3 hours following the administration of a tracer dose of [U-14C]palmitic acid. Administration of tetracycline, 0.0625, 0.25 or 1 mmole per kg, 6 hr before the measurement, increased hepatic triglycerides by 100, 170 and 250%, respectively. After 1 mmole per kg, accumulation of hepatic triglycerides was maximum at 24 hr, reaching 9-fold the control value; liver histology showed microvesicular steatosis at 6 and 24 hr. We conclude that tetracycline inhibits the mitochondrial oxidation of fatty acids in mice and in man.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Fatty Acids/metabolism , Fatty Liver/chemically induced , Mitochondria, Liver/drug effects , Tetracycline/pharmacology , Animals , Biopsy , Cells, Cultured , Depression, Chemical , Dose-Response Relationship, Drug , Fatty Liver/metabolism , Humans , Lipid Metabolism , Liver/pathology , Male , Mice , Mitochondria, Liver/metabolism , Oxidation-Reduction/drug effects , Tetracycline/adverse effects , Time Factors
20.
Gut ; 29(9): 1265-9, 1988 Sep.
Article in English | MEDLINE | ID: mdl-3198003

ABSTRACT

A patient with acute myeloblastic leukaemia developed jaundice revealing peliosis hepatis after receiving 6-thioguanine for two months. Peliosis hepatis was severe and was associated with mild lesions of centrilobular veins. Withdrawal of 6-thioguanine was followed by a progressive improvement of liver dysfunction. This report shows that 6-thioguanine, a thiopurine already reported to be responsible for veno-occlusive disease of the liver, can induce peliosis hepatis. This suggests that some liver vascular disorders caused by thiopurines (6-thioguanine, azathioprine and 6-mercaptopurine), particularly peliosis hepatis, veno-occlusive disease, sinusoidal dilatation and perisinusoidal fibrosis, might be related syndromes caused by similar lesions at different sites.


Subject(s)
Chemical and Drug Induced Liver Injury , Peliosis Hepatis/chemically induced , Thioguanine/adverse effects , Female , Humans , Leukemia, Myeloid, Acute/drug therapy , Middle Aged , Thioguanine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...